Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 16(6): e0253170, 2021.
Article in English | MEDLINE | ID: mdl-34133426

ABSTRACT

Clofarabine, an FDA approved purine analog, is used in the treatment of relapsed or refractory acute lymphoblastic leukemia. Clofarabine acts by inhibiting DNA synthesis. We demonstrated that clofarabine may have a novel function though inhibiting CD99, a transmembrane protein highly expressed on Ewing Sarcoma (ES) cells. CD99 is a validated target in ES whose inhibition may lead to a high therapeutic index for patients. Here we present additional data to support the hypothesis that clofarabine acts on CD99 and regulates key signaling pathways in ES. Cellular thermal shift assay indicated a direct interaction between clofarabine and CD99 in ES cell lysates. Clofarabine induced ES cell death does not require clofarabine's conversion to its active form by deoxycytidine kinase. A phosphokinase array screen with clofarabine and a CD99 blocking antibody identified alterations in signaling pathways. CD99 inhibition with clofarabine in ES cells caused rapid and sustained phosphorylation of ERK, MSK, and CREB. However, activation of this pathway did not correlate with clofarabine induced ES cell death. In summary, we demonstrated that clofarabine may activate ERK, MSK, and CREB phosphorylation through CD99 within minutes, however this paradoxical activation and subsequent ES cell death requires additional investigation.


Subject(s)
12E7 Antigen/antagonists & inhibitors , Antimetabolites, Antineoplastic/pharmacology , CREB-Binding Protein/metabolism , Clofarabine/pharmacology , MAP Kinase Signaling System/drug effects , Ribosomal Protein S6 Kinases, 90-kDa/metabolism , Sarcoma, Ewing/metabolism , Signal Transduction/drug effects , Blotting, Western , Cell Line, Tumor , Humans , Phosphorylation , Sarcoma, Ewing/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...